Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT01006889 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT01006889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01006889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
Lead sponsor
University of Florida
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2008
Completion date
February 28, 2010
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic fatty liver disease, type 2 diabetes mellitus